Top Stories
-
2 years ago
Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPILung01 Phase III trial
cadillacnews.com
-
2 years ago
Landmark Phase 3 MARIPOSA Study Shows RYBREVANT® (amivantamab-vmjw) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
wbtw.com
-
2 years ago
Inspirna Announces Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023
valdostadailytimes.com
-
2 years ago
The founder of startup Bonobos hid a bipolar diagnosis for decades. Now he’s on a mission to destigmatize mental health at work
fortune.com
-
2 years ago
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
kfor.com
-
2 years ago
CDR-Life Presents Precise Tumor and Patient Selection for CDR404: First-of-its-Kind Dual MAGE-A4 T-cell Engager, at ESMO Congress 2023
ksnt.com
-
2 years ago
CDR-Life Presents Precise Tumor and Patient Selection for CDR404: First-of-its-Kind Dual MAGE-A4 T-cell Engager, at ESMO Congress 2023
wgno.com
-
2 years ago
Azerbaijan's AZPROMO boosing cooperation with Madrid Chamber of Commerce and Industry
en.trend.az
-
2 years ago
The Eurostar rival aiming to shake-up cross-Channel travel
telegraph.co.uk